HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis

Abstract

Our results propose that the MTX induces the production of the anti-inflammatory sHLA-G molecules that concur with the therapy response. Furthermore, the association between -14/-14 bp genotype and MTX clinical outcome proposes this polymorphism as a therapy marker in the early phases of the disease.